Fujifilm Corporation has announced it will launch its Bio CDMO Division as a standalone unit on March 1, 2017 to expand its contract development and manufacturing operations for biopharmaceuticals. In this move, Fujifilm is separating its biopharmaceuticals contract development and manufacturing operations from its Pharmaceutical Products Division to form the Bio CDMO Division, which will also deal with contract development and manufacturing of small molecule pharmaceuticals.

Fujifilm conducts its biopharmaceuticals contract development and manufacturing business primarily at Fujifilm Diosynth Biotechnologies USA, Inc. and Fujifilm Diosynth Biotechnologies UK Limited. The company uses mammalian cell-based and microbial cell-based biomanufacturing. As part of its expansion into the biopharmaceuticals arena, Fujifilm acquired Kalon Biotherapeutics in 2014, which is now Fujifilm Diosynth Biotechnologies Texas, which specializes in vaccine manufacturing and high-potency low-volume manufacturing. Fujifilm’s capabilities in biomanufacturing include its Apollo technology, a mammalian expression platform. Fujifilm has has also made capital investments to reinforce its capabilities.

Source: FujiFilm